Scotiabank lowered the firm’s price target on Syndax (SNDX) to $16 from $18 and keeps a Sector Perform rating on the shares. The firm adjusted its price target on the stock based on its revised market share estimates for ziftomenib in relapsed/refractory KMT2Ar acute lymphoblastic leukemia and front-line acute leukemia treatment settings, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNDX: